Merck.com - Research and Development News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting®
Dateline City: KENILWORTH, N.J. Patients with Compensated Liver Cirrhosis Among Most Difficult-to-Treat KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvi...
Source: Merck.com - Research and Development News - November 15, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hep C Hepatitis C MSD NYSE:MRK Source Type: news

Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
Dateline City: KENILWORTH, N.J. Results from C-EDGE CO-STAR Presented at The Liver Meeting® Show High Sustained Virologic Response After 12 Weeks of Treatment KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company’s Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50...
Source: Merck.com - Research and Development News - November 15, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Hep C Hepatitis C MSD NYSE:MRK Source Type: news

Merck Provides Update on REVEAL Outcomes Study
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Data Monitoring Committee (DMC) of the REVEAL outcomes study for anacetrapib has completed its planned review of unblinded study data and recommended the study continue with no changes. The DMC reviewed safety and efficacy data from the study, which included an assessment of futility. Merck remains blinded to the actual results of this analysis and to other REVEAL saf...
Source: Merck.com - Research and Development News - November 13, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News anacetrapib Merck MRK MSD NYSE:MRK REVEAL Source Type: news

Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting
Dateline City: KENILWORTH, N.J. One-Year Phase 3 Data for Investigational Biosimilar Candidates SB4, Enbrel (Etanercept) and SB2, Remicade (Infliximab) to be Presented for the First Time New Pivotal 24-Week Phase 3 Data for SB5, an Investigational Biosimilar of Humira (Adalimumab), to be Reported in Late-Breaking Presentation KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Sam...
Source: Merck.com - Research and Development News - November 5, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting® 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations
Dateline City: KENILWORTH, N.J. New Data Will Also be Presented from Phase 2a C-CREST Trials of Merck’s Investigational Triple-Combination Chronic Hepatitis C Therapies KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data from clinical trials of its investigational treatment portfolio for chronic hepatitis C virus (HCV) are scheduled to be presented at The Liver Meeting® 2015 (the ...
Source: Merck.com - Research and Development News - October 20, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news

Results from Merck’s Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naïve and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Language: ...
Source: Merck.com - Research and Development News - October 5, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news

Syndax and Merck Announce First Patients Dosed in Phase 1b/2 Clinical Trial of Entinostat and KEYTRUDA®
Dateline City: WALTHAM, Mass. and KENILWORTH, N.J. Clinical trial to assess safety and efficacy of immuno-oncology combination in patients with advanced NSCLC or melanoma WALTHAM, Mass. and KENILWORTH, N.J. – Syndax Pharmaceuticals, Inc. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndax’s entinostat in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with non...
Source: Merck.com - Research and Development News - September 28, 2015 Category: Pharmaceuticals Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news

Pivotal Phase 3 Studies of Bezlotoxumab, Merck’s Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint
Dateline City: KENILWORTH, N.J. Company Plans to Submit New Drug Applications in U.S., EU and Canada in 2015 Results Presented for the First Time at ICAAC/ICC 2015 Annual Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recu...
Source: Merck.com - Research and Development News - September 20, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015
Dateline City: KENILWORTH, N.J. Company Initiates Pivotal Phase 3 Studies Evaluating Relebactam in Combination with Imipenem/Cilastatin for Treatment of Serious Bacterial Infections KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company’s investigational beta-lactamase inhibitor for the treatment, in combination with imipenem/cilastatin (an approved c...
Source: Merck.com - Research and Development News - September 18, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes
Dateline City: KENILWORTH, N.J. Presents Pivotal Data for Omarigliptin, Merck’s Investigational Once-Weekly DPP-4 Inhibitor, and Additional Data from the TECOS CV Safety Trial, at European Association for the Study of Diabetes Annual Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, provided an update today on its diabetes portfolio and re-affirmed the company’s comprehensive, long-term commitment ...
Source: Merck.com - Research and Development News - September 17, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

Merck’s Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA® (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that omarigliptin, Merck’s investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Merck’s once-daily DPP-4 inhibitor, JANUVIA® (sitagliptin), at reducing patients’ A1C* levels from baseline, with similar A1C reductions achieved in ...
Source: Merck.com - Research and Development News - September 16, 2015 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news

New Analyses from the IMPROVE-IT Study with VYTORIN® (ezetimibe and simvastatin)
Dateline City: KENILWORTH, N.J. Further Analyses on the Long-Term Safety and Efficacy of VYTORIN® from the IMPROVE-IT Study Presented at the European Society of Cardiology (ESC) Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD in the United States and Canada, today announced results from new analyses from the IMPROVE-IT study. “IMPROVE-IT presents us with the opportunity to look at cardiovascular outcomes data for patients trea...
Source: Merck.com - Research and Development News - September 1, 2015 Category: Pharmaceuticals Tags: Research and Development News Source Type: news

In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing
Dateline City: KENILWORTH, N.J. Global Collaboration Enabled Vaccine to Move from First-in-Human Studies to Initial Phase 3 Results Within One Year KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (known as MSD outside the US and Canada) said today that its investigational Ebola vaccine candidate, rVSV-ZEBOV, was found to have 100 percent efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea. Preliminary conclusions from this study, which...
Source: Merck.com - Research and Development News - July 31, 2015 Category: Pharmaceuticals Tags: Ebola Newsroom Research and Development News Corporate News Latest News Source Type: news

Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection
Dateline City: KENILWORTH, N.J. Company Granted FDA Priority Review with Target Action Date of January 28, 2016 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Language: English Contact: MerckMedia:Doris Li, (908) 246-5701Sarra Herzog, (201) 669-6570orInvestor:...
Source: Merck.com - Research and Development News - July 28, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news

Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a marketing authorization application (MAA) for grazoprevir/elbasvir (100mg/50mg), an investigational, once-daily, single-tablet combination therapy for the treatment of adult patients with chronic hepatitis C (HCV) genotypes (GT) 1, 3, 4 or 6 infection.1 The EMA will initiate review of the MAA under accelerated asses...
Source: Merck.com - Research and Development News - July 23, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news